A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Trial Details

NCT ID
NCT06150664
Phase
PHASE1
Sponsor
Compass Therapeutics
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Palo Alto, California, United States|37.44188,-122.14302
  • Margate, Florida, United States|26.24453,-80.20644
  • Orlando, Florida, United States|28.53834,-81.37924
  • Sarasota, Florida, United States|27.33643,-82.53065

Key Eligibility Criteria

  • Age 18 years or older
  • Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/re…
  • Malignant Melanoma (MM)
  • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →